PUMA BIOTECHNOLOGY, INC. Revenue
PUMA BIOTECHNOLOGY, INC. (PBYI) reported Revenue of $56.50 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-06
- PUMA BIOTECHNOLOGY, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $56.50M, a 7.75% increase year-over-year.
- PUMA BIOTECHNOLOGY, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $44.81M, a 2.59% decline year-over-year.
- PUMA BIOTECHNOLOGY, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $75.45M, a 27.72% increase year-over-year.
- PUMA BIOTECHNOLOGY, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $54.48M, a 32.36% decline year-over-year.
- PUMA BIOTECHNOLOGY, INC. revenue from contract with customer, excluding assessed tax for fiscal 2025 was $228.37M, a 0.91% decline from fiscal 2024.
- PUMA BIOTECHNOLOGY, INC. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $230.47M, a 2.19% decline from fiscal 2023.
- PUMA BIOTECHNOLOGY, INC. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $235.64M, a 3.34% increase from fiscal 2022.
- PUMA BIOTECHNOLOGY, INC. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $228.03M, a 9.92% decline from fiscal 2021.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $56.50M 10-Q · filed 2026-08-06 | $101.32M 10-Q · filed 2026-08-06 | $176.77M derived: sum of 3 quarters · filed 2026-08-06 | $231.24M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $44.81M 10-Q · filed 2026-05-07 | $120.27M derived: sum of 2 quarters · filed 2026-05-07 | $174.74M derived: sum of 3 quarters · filed 2026-05-07 | $227.18M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $75.45M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $129.93M derived: sum of 2 quarters · filed 2026-02-26 | $182.36M derived: sum of 3 quarters · filed 2026-08-06 | $228.37M 10-K · filed 2026-02-26 |
| 2025-09-30 | $54.48M 10-Q · filed 2025-11-06 | $106.91M derived: sum of 2 quarters · filed 2026-08-06 | $152.92M 10-Q · filed 2025-11-06 | $212.00M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $52.44M 10-Q · filed 2026-08-06 | $98.44M 10-Q · filed 2026-08-06 | $157.52M derived: sum of 3 quarters · filed 2026-08-06 | $238.06M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $46.01M 10-Q · filed 2026-05-07 | $105.08M derived: sum of 2 quarters · filed 2026-05-07 | $185.63M derived: sum of 3 quarters · filed 2026-05-07 | $232.71M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $59.08M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $139.62M derived: sum of 2 quarters · filed 2026-02-26 | $186.70M derived: sum of 3 quarters · filed 2026-02-26 | $230.47M 10-K · filed 2026-02-26 |
| 2024-09-30 | $80.54M 10-Q · filed 2025-11-06 | $127.63M derived: sum of 2 quarters · filed 2025-11-06 | $171.39M 10-Q · filed 2025-11-06 | $243.57M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $47.08M 10-Q · filed 2025-08-07 | $90.85M 10-Q · filed 2025-08-07 | $163.03M derived: sum of 3 quarters · filed 2026-02-26 | $219.14M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $43.77M 10-Q · filed 2025-05-08 | $115.94M derived: sum of 2 quarters · filed 2026-02-26 | $172.06M derived: sum of 3 quarters · filed 2026-02-26 | $226.63M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $72.18M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $128.29M derived: sum of 2 quarters · filed 2026-02-26 | $182.86M derived: sum of 3 quarters · filed 2026-02-26 | $235.64M 10-K · filed 2026-02-26 |
| 2023-09-30 | $56.12M 10-Q · filed 2024-11-07 | $110.68M derived: sum of 2 quarters · filed 2024-11-07 | $163.46M 10-Q · filed 2024-11-07 | $229.13M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $54.57M 10-Q · filed 2024-08-01 | $107.34M 10-Q · filed 2024-08-01 | $173.02M derived: sum of 3 quarters · filed 2025-02-27 | $230.12M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $52.77M 10-Q · filed 2024-05-02 | $118.45M derived: sum of 2 quarters · filed 2025-02-27 | $175.55M derived: sum of 3 quarters · filed 2025-02-27 | $235.07M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $65.67M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $122.78M derived: sum of 2 quarters · filed 2025-02-27 | $182.29M derived: sum of 3 quarters · filed 2025-02-27 | $228.03M 10-K · filed 2025-02-27 |
| 2022-09-30 | $57.10M 10-Q · filed 2023-11-02 | $116.62M derived: sum of 2 quarters · filed 2023-11-02 | $162.36M 10-Q · filed 2023-11-02 | $217.71M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $59.52M 10-Q · filed 2023-08-03 | $105.25M 10-Q · filed 2023-08-03 | $160.61M derived: sum of 3 quarters · filed 2024-02-29 | $206.86M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $45.74M 10-Q · filed 2023-05-04 | $101.09M derived: sum of 2 quarters · filed 2024-02-29 | $147.34M derived: sum of 3 quarters · filed 2024-02-29 | $200.72M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | $55.36M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $101.60M derived: sum of 2 quarters · filed 2024-02-29 | $154.99M derived: sum of 3 quarters · filed 2024-02-29 | $253.16M 10-K · filed 2024-02-29 |
| 2021-09-30 | $46.24M 10-Q · filed 2022-11-03 | $99.63M derived: sum of 2 quarters · filed 2022-11-03 | $197.80M 10-Q · filed 2022-11-03 | $250.35M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | $53.38M 10-Q · filed 2022-08-04 | $151.55M 10-Q · filed 2022-08-04 | $204.11M derived: sum of 3 quarters · filed 2022-08-04 | $254.86M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | $98.17M 10-Q · filed 2022-05-05 | $150.73M derived: sum of 2 quarters · filed 2022-05-05 | $201.48M derived: sum of 3 quarters · filed 2022-05-05 | $272.06M derived: sum of 4 quarters · filed 2022-05-05 |
| 2020-12-31 | $52.56M 10-K · filed 2021-03-01 | $103.31M derived: sum of 2 quarters · filed 2021-11-04 | $173.89M derived: sum of 3 quarters · filed 2021-11-04 | $225.11M 10-K · filed 2023-03-02 |
| 2020-09-30 | $50.75M 10-Q · filed 2021-11-04 | $121.34M derived: sum of 2 quarters · filed 2021-11-04 | $172.55M 10-Q · filed 2021-11-04 | $235.47M derived: sum of 4 quarters · filed 2021-11-04 |
| 2020-06-30 | $70.58M 10-Q · filed 2021-08-05 | $121.80M 10-Q · filed 2021-08-05 | $184.72M derived: sum of 3 quarters · filed 2021-08-05 | $241.07M derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | $51.22M 10-Q · filed 2021-05-06 | $114.14M derived: sum of 2 quarters · filed 2021-05-06 | $170.49M derived: sum of 3 quarters · filed 2021-05-06 | $224.41M derived: sum of 4 quarters · filed 2021-05-06 |
| 2019-12-31 | $62.92M 10-K · filed 2021-03-01 | $119.27M derived: sum of 2 quarters · filed 2021-03-01 | $173.19M derived: sum of 3 quarters · filed 2021-03-01 | $272.26M 10-K · filed 2022-03-03 |
| 2019-09-30 | $56.35M 10-K · filed 2021-03-01 | $110.27M derived: sum of 2 quarters · filed 2021-03-01 | $209.34M 10-Q · filed 2020-11-05 | $280.42M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | $53.92M 10-K · filed 2021-03-01 | $152.99M 10-Q · filed 2020-08-06 | $224.06M derived: sum of 3 quarters · filed 2021-03-01 | $286.69M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | $99.07M 10-K · filed 2021-03-01 | $170.15M derived: sum of 2 quarters · filed 2021-03-01 | $232.78M derived: sum of 3 quarters · filed 2021-03-01 | $283.54M derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | $71.08M 10-K · filed 2021-03-01 | $133.71M derived: sum of 2 quarters · filed 2021-03-01 | $184.47M derived: sum of 3 quarters · filed 2021-03-01 | $250.99M 10-K · filed 2021-03-01 |
| 2018-09-30 | $62.63M 10-K · filed 2021-03-01 | $113.40M derived: sum of 2 quarters · filed 2021-03-01 | $179.91M 10-Q · filed 2019-11-07 | $201.52M derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-06-30 | $50.77M 10-K · filed 2021-03-01 | $117.28M 10-Q · filed 2019-08-09 | $138.89M derived: sum of 3 quarters · filed 2021-03-01 | $144.97M derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-03-31 | $66.52M 10-K · filed 2021-03-01 | $88.12M derived: sum of 2 quarters · filed 2021-03-01 | $94.20M derived: sum of 3 quarters · filed 2021-03-01 | |
| 2017-12-31 | $21.61M 10-K · filed 2020-02-28 | $27.68M derived: sum of 2 quarters · filed 2020-02-28 | $27.68M 10-K · filed 2020-02-28 | |
| 2017-09-30 | $6.08M 10-K · filed 2020-02-28 | $6.08M 10-Q · filed 2018-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |